ChromaDex (CDXC) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

CDXC Stock Forecast

ChromaDex stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

CDXC Analyst Ratings

Buy

According to 1 Wall Street analysts, ChromaDex's rating consensus is 'Buy'. The analyst rating breakdown for CDXC stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jun 18, 2022	H.C. Wainwright	Buy	Buy	Hold

Row per page

Go to

ChromaDex's last stock rating was published by H.C. Wainwright on Jun 18, 2022. The company gave CDXC a "Buy" rating, the same as its previous rate.

ChromaDex Financial Forecast

ChromaDex Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$29.45M	$27.02M	-	$22.56M	$21.00M	$17.06M	$16.73M	$17.26M	$17.76M	$17.31M	$17.70M	$14.68M	$15.45M	$14.18M	$15.29M	$14.35M	$13.09M	$12.05M
Avg Forecast	$36.38M	$35.23M	$32.41M	$31.82M	$31.53M	$30.50M	$28.54M	$27.74M	$26.79M	$24.03M	$23.32M	$23.48M	$20.81M	$20.30M	$19.42M	$19.41M	$21.14M	$18.69M	$18.68M	$17.52M	$18.57M	$17.18M	$17.16M	$16.68M	$15.36M	$14.29M	$14.32M	$13.59M	$12.97M	$11.52M
High Forecast	$37.73M	$36.54M	$33.62M	$33.01M	$32.71M	$31.63M	$29.60M	$28.18M	$27.67M	$24.03M	$24.19M	$24.35M	$21.31M	$21.05M	$20.14M	$20.13M	$21.92M	$18.69M	$18.68M	$17.52M	$18.57M	$17.18M	$17.16M	$16.68M	$15.36M	$14.29M	$14.32M	$13.59M	$12.97M	$11.52M
Low Forecast	$34.89M	$33.78M	$31.09M	$30.52M	$30.24M	$29.25M	$27.37M	$27.31M	$25.90M	$24.03M	$22.37M	$22.51M	$20.31M	$19.46M	$18.62M	$18.61M	$20.27M	$18.69M	$18.68M	$17.52M	$18.57M	$17.18M	$17.16M	$16.68M	$15.36M	$14.29M	$14.32M	$13.59M	$12.97M	$11.52M
# Analysts	1	1	1	1	1	1	1	3	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	5	5
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.42%	1.33%	-	1.16%	0.99%	0.91%	0.90%	0.98%	0.96%	1.01%	1.03%	0.88%	1.01%	0.99%	1.07%	1.06%	1.01%	1.05%

ChromaDex's average Quarter revenue forecast for Mar 24 based on 1 analysts is $23.48M, with a low forecast of $22.51M, and a high forecast of $24.35M. CDXC's average Quarter revenue forecast represents a -20.30% decrease compared to the company's last Quarter revenue of $29.45M (Dec 23).

ChromaDex EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	5	5
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-168.00K	$-1.15M	-	$-1.97M	$-1.44M	$-531.00K	$-5.96M	$-7.18M	$-4.93M	$-8.43M	$-5.14M	$-6.96M	$-5.69M	$-3.82M	$-3.31M	$-5.52M	$-8.50M	$-6.49M
Avg Forecast	$-11.71M	$-11.34M	$-10.43M	$-10.24M	$-10.15M	$-9.81M	$-9.18M	$-8.93M	$-8.62M	$-7.73M	$-7.51M	$-7.55M	$-6.70M	$-6.53M	$-6.25M	$-6.24M	$-6.80M	$-6.25M	$-6.25M	$-5.59M	$-6.21M	$-5.75M	$-5.74M	$-4.64M	$-5.14M	$-4.78M	$-4.79M	$-6.04M	$-4.34M	$-3.86M
High Forecast	$-11.23M	$-10.87M	$-10.00M	$-9.82M	$-9.73M	$-9.41M	$-8.81M	$-8.79M	$-8.33M	$-7.73M	$-7.20M	$-7.24M	$-6.54M	$-6.26M	$-5.99M	$-5.99M	$-6.52M	$-6.25M	$-6.25M	$-4.47M	$-6.21M	$-5.75M	$-5.74M	$-3.71M	$-5.14M	$-4.78M	$-4.79M	$-4.83M	$-4.34M	$-3.86M
Low Forecast	$-12.14M	$-11.76M	$-10.82M	$-10.62M	$-10.53M	$-10.18M	$-9.52M	$-9.07M	$-8.91M	$-7.73M	$-7.79M	$-7.84M	$-6.86M	$-6.77M	$-6.48M	$-6.48M	$-7.06M	$-6.25M	$-6.25M	$-6.70M	$-6.21M	$-5.75M	$-5.74M	$-5.56M	$-5.14M	$-4.78M	$-4.79M	$-7.24M	$-4.34M	$-3.86M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.03%	0.18%	-	0.32%	0.21%	0.08%	0.95%	1.29%	0.79%	1.47%	0.89%	1.50%	1.11%	0.80%	0.69%	0.91%	1.96%	1.68%

undefined analysts predict CDXC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ChromaDex's previous annual EBITDA (undefined) of $NaN.

ChromaDex Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	5	5
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$114.00K	$-959.00K	-	$-1.33M	$673.00K	$1.09M	$-6.41M	$-7.75M	$-5.33M	$-8.87M	$-5.58M	$-7.40M	$-6.11M	$-4.23M	$-3.73M	$-5.93M	$-8.84M	$-7.20M
Avg Forecast	$3.89M	$3.89M	$2.72M	$2.33M	$3.50M	$2.92M	$2.33M	$1.54M	$1.75M	$445.22K	$-1.56M	$-1.56M	$-1.75M	$-2.33M	$-3.11M	$-3.62M	$-1.94M	$-4.66M	$-6.35M	$-6.02M	$-7.50M	$-6.98M	$-6.20M	$-4.92M	$-7.18M	$-7.40M	$-7.56M	$-6.44M	$-8.16M	$-8.31M
High Forecast	$4.08M	$4.08M	$2.85M	$2.45M	$3.67M	$3.06M	$2.45M	$1.55M	$1.83M	$455.91K	$-1.47M	$-1.47M	$-1.66M	$-2.21M	$-2.95M	$-3.43M	$-1.84M	$-4.66M	$-6.35M	$-4.82M	$-7.50M	$-6.98M	$-6.20M	$-3.94M	$-7.18M	$-7.40M	$-7.56M	$-5.15M	$-8.16M	$-8.31M
Low Forecast	$3.68M	$3.68M	$2.58M	$2.21M	$3.31M	$2.76M	$2.21M	$1.53M	$1.66M	$434.53K	$-1.63M	$-1.63M	$-1.83M	$-2.45M	$-3.26M	$-3.80M	$-2.04M	$-4.66M	$-6.35M	$-7.22M	$-7.50M	$-6.98M	$-6.20M	$-5.90M	$-7.18M	$-7.40M	$-7.56M	$-7.73M	$-8.16M	$-8.31M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-0.07%	0.41%	-	0.37%	-0.35%	-0.24%	1.01%	1.29%	0.71%	1.27%	0.90%	1.50%	0.85%	0.57%	0.49%	0.92%	1.08%	0.87%

ChromaDex's average Quarter net income forecast for Mar 24 is $-1.56M, with a range of $-1.63M to $-1.47M. CDXC's average Quarter net income forecast represents a -1464.35% decrease compared to the company's last Quarter net income of $114.00K (Dec 23).

ChromaDex SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	5	5
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$11.95M	$11.88M	-	$14.29M	$12.18M	$12.05M	$15.18M	$17.19M	$15.14M	$18.42M	$15.36M	$15.77M	$14.51M	$11.77M	$11.83M	$13.28M	$15.19M	$12.59M
Avg Forecast	$31.74M	$30.73M	$28.28M	$27.77M	$27.51M	$26.61M	$24.90M	$24.21M	$23.37M	$20.97M	$20.35M	$20.48M	$18.16M	$17.71M	$16.94M	$16.93M	$18.44M	$16.14M	$16.13M	$13.37M	$16.04M	$14.83M	$14.82M	$10.51M	$13.27M	$12.34M	$12.37M	$11.73M	$11.20M	$9.95M
High Forecast	$32.92M	$31.88M	$29.34M	$28.80M	$28.54M	$27.60M	$25.82M	$24.59M	$24.15M	$20.97M	$21.11M	$21.24M	$18.60M	$18.37M	$17.57M	$17.56M	$19.13M	$16.14M	$16.13M	$16.04M	$16.04M	$14.83M	$14.82M	$12.62M	$13.27M	$12.34M	$12.37M	$11.73M	$11.20M	$9.95M
Low Forecast	$30.44M	$29.48M	$27.12M	$26.63M	$26.39M	$25.52M	$23.88M	$23.82M	$22.59M	$20.97M	$19.52M	$19.64M	$17.72M	$16.98M	$16.25M	$16.24M	$17.69M	$16.14M	$16.13M	$10.69M	$16.04M	$14.83M	$14.82M	$8.41M	$13.27M	$12.34M	$12.37M	$11.73M	$11.20M	$9.95M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.66%	0.67%	-	0.84%	0.66%	0.75%	0.94%	1.29%	0.94%	1.24%	1.04%	1.50%	1.09%	0.95%	0.96%	1.13%	1.36%	1.27%

ChromaDex's average Quarter SG&A projection for Mar 24 is $20.48M, based on 1 Wall Street analysts, with a range of $19.64M to $21.24M. The forecast indicates a 71.46% rise compared to CDXC last annual SG&A of $11.95M (Dec 23).

ChromaDex EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	5	5
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.01	-	$-0.02	$0.01	$0.02	$-0.09	$-0.11	$-0.08	$-0.13	$-0.08	$-0.12	$-0.10	$-0.07	$-0.06	$-0.10	$-0.15	$-0.14
Avg Forecast	$0.05	$0.05	$0.04	$0.03	$0.04	$0.04	$0.03	$0.02	$0.02	$0.01	$-0.02	$-0.02	$-0.02	$-0.03	$-0.04	$-0.05	$-0.03	$-0.06	$-0.08	$-0.09	$-0.10	$-0.09	$-0.08	$-0.09	$-0.10	$-0.10	$-0.10	$-0.11	$-0.11	$-0.11
High Forecast	$0.05	$0.05	$0.04	$0.03	$0.05	$0.04	$0.03	$0.02	$0.02	$0.01	$-0.02	$-0.02	$-0.02	$-0.03	$-0.04	$-0.04	$-0.02	$-0.06	$-0.08	$-0.09	$-0.10	$-0.09	$-0.08	$-0.09	$-0.10	$-0.10	$-0.10	$-0.11	$-0.11	$-0.11
Low Forecast	$0.05	$0.05	$0.03	$0.03	$0.04	$0.04	$0.03	$0.02	$0.02	$0.01	$-0.02	$-0.02	$-0.02	$-0.03	$-0.04	$-0.05	$-0.03	$-0.06	$-0.08	$-0.09	$-0.10	$-0.09	$-0.08	$-0.09	$-0.10	$-0.10	$-0.10	$-0.11	$-0.11	$-0.11
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-0.07%	0.43%	-	0.38%	-0.36%	-0.26%	1.12%	1.24%	0.79%	1.41%	1.00%	1.40%	1.04%	0.70%	0.61%	0.90%	1.39%	1.27%

According to 1 Wall Street analysts, ChromaDex's projected average Quarter EPS for Mar 24 is $-0.02, with a low estimate of $-0.02 and a high estimate of $-0.02. This represents a -1433.33% decrease compared to CDXC previous annual EPS of - (Dec 23).

ChromaDex Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
IPSC	Century Therapeutics	$1.28	$15.00	1071.88%	Buy
NGM	NGM Biopharmaceuticals	$1.54	$16.50	971.43%	Buy
NKTX	Nkarta	$2.48	$21.60	770.97%	Buy
ANTX	AN2 Therapeutics	$1.06	$8.75	725.47%	Buy
AVTE	Aerovate Therapeutics	$2.67	$13.00	386.89%	Hold
ANEB	Anebulo Pharmaceuticals	$1.52	$6.00	294.74%	Buy
ACRV	Acrivon Therapeutics	$6.38	$21.83	242.16%	Buy
RZLT	Rezolute	$4.95	$13.50	172.73%	Buy
ELYM	Eliem Therapeutics	$5.11	$13.00	154.40%	Buy
KZR	Kezar Life Sciences	$7.38	$17.50	137.13%	Buy
MLYS	Mineralys Therapeutics	$12.86	$30.00	133.28%	Buy
ADAG	Adagene	$2.22	$5.00	125.23%	Buy
XCUR	Exicure	$5.82	$12.00	106.19%	-
JANX	Janux Therapeutics	$49.01	$61.20	24.87%	Buy
IKNA	Ikena Oncology	$1.68	$1.33	-20.83%	Buy
CDXC	ChromaDex	$7.52	$5.50	-26.86%	Buy
CYT	Cyteir Therapeutics	$3.02	$2.00	-33.77%	Sell

CDXC Forecast FAQ

Is ChromaDex a good buy?

Yes, according to 1 Wall Street analysts, ChromaDex (CDXC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of CDXC's total ratings.

What are ChromaDex's analysts' financial forecasts?

ChromaDex's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $118.3M (high $122.11M, low $114.16M), average EBITDA is $-38.072M (high $-36.737M, low $-39.297M), average net income is $10.28M (high $10.72M, low $9.81M), average SG&A $103.22M (high $106.55M, low $99.6M), and average EPS is $0.132 (high $0.138, low $0.126). CDXC's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $135.84M (high $140.9M, low $130.28M), average EBITDA is $-43.716M (high $-41.925M, low $-45.344M), average net income is $12.83M (high $13.45M, low $12.15M), average SG&A $118.53M (high $122.94M, low $113.67M), and average EPS is $0.165 (high $0.173, low $0.156).

Did the CDXC's actual financial results beat the analysts' financial forecasts?

Based on ChromaDex's last annual report (Dec 2023), the company's revenue was $116.36M, beating the average analysts forecast of $79.93M by 45.57%. Apple's EBITDA was $-5.599M, missing the average prediction of $-25.723M by -78.23%. The company's net income was $-4.938M, missing the average estimation of $-10.816M by -54.35%. Apple's SG&A was $51.42M, missing the average forecast of $69.74M by -26.27%. Lastly, the company's EPS was $-0.0659, missing the average prediction of $-0.139 by -52.62%. In terms of the last quarterly report (Dec 2023), ChromaDex's revenue was $29.46M, beating the average analysts' forecast of $20.81M by 41.53%. The company's EBITDA was $-168K, missing the average prediction of $-6.698M by -97.49%. ChromaDex's net income was $114K, missing the average estimation of $-1.75M by -106.52%. The company's SG&A was $11.95M, missing the average forecast of $18.16M by -34.21%. Lastly, the company's EPS was $0.0015, missing the average prediction of $-0.0225 by -106.67%